Thomas Stephen Basil sold CLYM

September 15, 2026 · Form 4 insider transaction

Thomas Stephen Basil sold 100,000 shares of Climb Bio Inc at $13.67 per share, a transaction worth $1.37M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
100,000
Price
$13.67
Total value
$1.37M
RoleDirector
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateSeptember 15, 2026
Filing dateSeptember 17, 2026
Shares owned after467,969
OwnershipDirect
10b5-1 planYes
AmendedNo

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.; The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.; Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.

View the original Form 4 on SEC EDGAR
Thomas Stephen Basil sold CLYM: September 15, 2026 | Insider Trading Screener